RaDaR Residual Disease and Recurrence
RaDaR™ is a personalized, multi-tumor liquid biopsy assay that can track a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity. This allows RaDaR™ to detect traces of molecular residual disease (MRD) in a patient following surgery or other treatment for cancer, enabling early detection of relapse and accurate monitoring.
Reliable detection of residual disease and recurrence from a simple blood draw
What is RaDaR™?
RaDaR™ is a multi-tumor, personalized blood test able to detect residual disease and recurrence with exceptional sensitivity.
By tracking up to 48 tumor-specific variants in a patient from a simple blood draw, RaDaR™ detects traces of cancerous DNA circulating through the body (known as circulating tumor DNA or ctDNA).
This allows for the detection of molecular residual disease (MRD) in patients after cancer treatment, and even the early detection of relapse.
What is Molecular Residual Disease?
Even when a patient’s tumor is removed or treated, there is always a risk that the cancer could come back. Unfortunately, in all too many cases this proves to be true. This indicates that some residual disease from that cancer was still present in the body, even after treatment with curative intent.
Molecular residual disease, or MRD, refers to these small traces of cancer that remain in a patient’s body. This residual disease may only be present at very low levels, making it hard for tests to spot. Left unrecognized, this residual disease may eventually cause the cancer to come back.
There is a significant need to help clinicians and cancer patients spot the signs of recurrence and remaining traces of disease early and quickly.
Built on Inivata’s proven InVision® liquid biopsy platform technology, RaDaR™ has been carefully designed and optimized to detect extremely low levels of ctDNA in the blood, enabling clinicians to detect relapse with high confidence, much earlier than many other available tools.
RaDaR™ has demonstrated exceptionally high sensitivity and specificity in detecting truly tiny amounts of cancer DNA. Our analytical validation data demonstrate a Limit of Detection (LoD95%) of 0.0011% variant allele fraction (VAF) with 100% specificity.
With a rapid turnaround time of seven calendar days from blood draw to result once the personalized assay is built, RaDaR™ helps patients in situations where every second counts.
Industry-leading plasma NGS technology provides higher resolution information
Identification of true MRD signals with high confidence without false positives
Real-world clinical evidence across different solid cancers